Group 1 for Multiple Myeloma
This trial is testing the safety of CT-011 and the combination of the Dendritic cell fusion vaccine and CT-011 after ASCT in patients with multiple myeloma. They are also testing to see if the combination is more successful in preventing or delaying the disease from coming back, compared to treatment with ASCT alone.
- Multiple Myeloma
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many participants is the research team recruiting for this clinical experiment?
"This trial is no longer accepting participants. It was first posted on March 1st 2010, and the most recent amendment to it took place on September 5th 2022. Currently there are 807 studies seeking patients with multiple myeloma and one study searching for Group 2 subjects."
Is Group 2 a viable option for patients with regards to safety?
"Group 2's safety was evaluated and assessed as a score of 2, given that there is existing data validating its security but none currently affirming its efficacy."
Are there any opportunities for participants to join this experiment?
"Unfortunately, this medical study is no longer enrolling patients. Initially posted on March 1st 2010 and last edited September 5th 2022, any prospective participants are encouraged to check out the 807 studies actively searching for individuals with multiple myeloma or the single trial looking for Group 2 applicants."
Could you provide me with an overview of the other experiments carried out in relation to Group 2?
"At the current moment, only 1 research project concerning Group 2 is active with 0 Phase 3 trials. These studies are mainly held in Boston but also span to other locations."